APDN 8-K: Discloses Active Communications Under SEC Rules

Ticker: BNBX · Form: 8-K · Filed: Jan 8, 2024 · CIK: 744452

Applied Dna Sciences INC 8-K Filing Summary
FieldDetail
CompanyApplied Dna Sciences INC (BNBX)
Form Type8-K
Filed DateJan 8, 2024
Risk Levelmedium
Pages2
Reading Time3 min
Key Dollar Amounts$0.001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulation-fd, corporate-communications, sec-filing

TL;DR

**APDN filed an 8-K indicating active communications for potential major corporate actions.**

AI Summary

Applied DNA Sciences, Inc. filed an 8-K on January 8, 2024, primarily to disclose that it is satisfying its filing obligations under various SEC rules, including Rule 425 under the Securities Act and Rule 14a-12 under the Exchange Act. This filing indicates the company is actively engaged in communications related to potential corporate actions, which could impact shareholders by signaling upcoming events like mergers, acquisitions, or significant proxy solicitations that might affect the stock's value or ownership structure.

Why It Matters

This filing signals that Applied DNA Sciences is actively communicating about significant corporate events, which could lead to material changes in the company's structure or operations, directly impacting shareholder value.

Risk Assessment

Risk Level: medium — The filing itself is administrative, but the underlying communications it references could carry significant risk or opportunity depending on their nature.

Analyst Insight

Investors should monitor subsequent filings or communications from Applied DNA Sciences for details on the specific events or transactions that triggered the need to satisfy these various SEC communication rules, as these could be material to the company's future.

Key Players & Entities

FAQ

What is the primary purpose of Applied DNA Sciences, Inc.'s 8-K filing on January 8, 2024?

The primary purpose of the 8-K filing on January 8, 2024, is to indicate that Applied DNA Sciences, Inc. is simultaneously satisfying its filing obligations under specific provisions, including Rule 425 under the Securities Act and Rule 14a-12 under the Exchange Act, among others.

Which specific SEC rules are mentioned in the 8-K filing that Applied DNA Sciences, Inc. is satisfying?

The filing explicitly states that Applied DNA Sciences, Inc. is satisfying obligations under Rule 425 under the Securities Act (17 CFR 230.425), Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12), Rule 14d-2(b) under the Exchange Act, and Rule 13e-4(c) under the Exchange Act.

What is the registrant's telephone number and business address as stated in the filing?

The registrant's telephone number is 631-240-8800, and its business address is 50 Health Sciences Drive, Stony Brook, New York 11790.

What is the Commission File Number for Applied DNA Sciences, Inc. according to this 8-K?

The Commission File Number for Applied DNA Sciences, Inc. is 001-36745.

Does the filing indicate if Applied DNA Sciences, Inc. is an emerging growth company?

No, the filing includes a checkbox for 'emerging growth company' but does not indicate whether the registrant is one, as the box is not checked or explicitly marked 'yes' or 'no'.

Filing Stats: 626 words · 3 min read · ~2 pages · Grade level 10.7 · Accepted 2024-01-08 07:00:26

Key Financial Figures

Filing Documents

01

Item 7.01 Regulation FD Disclosure. On January 8, 2024, Applied DNA Sciences, Inc. (the "Company") intends to make presentations entitled "A Next Generation Platform for Genetic Medicine Manufacturing" to investors and analysts attending various conferences in San Francisco, California. The presentation is available on the Company's website at www.adnas.com and it may also be used in presentations to investors and analysts from time to time in the future. A copy of the Company's presentation is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information contained in this Current Report on Form 8-K speaks only as of the date hereof. While the Company may elect to update the information in this Current Report on Form 8-K in the future, the Company disclaims any obligation to do so except to the extent required by applicable law. The information furnished in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise by reference into any filings of the Company made under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in the filing unless specifically stated so therein.

Financial Statements and Exhibits

Financial Statements and Exhibits. ( d) Exhibits 99.1 Presentation of Applied DNA Sciences, Inc. 104 Cover Page Interactive Data File (formatted in Inline XBRL). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 8, 2024 APPLIED DNA SCIENCES, INC. By: /s/ James A. Hayward Name: James A. Hayward

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing